{
      "Rank": 153,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Single intraarticular injection of Hyaluronic acid (Hyal One)",
            "Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells",
            "Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells"
      ],
      "ArmGroupInterventionName": [
            "Drug: Hyaluronic acid",
            "Drug: Hyaluronic acid",
            "Biological: 10 million Bone marrow mesenchimal stem cells",
            "Drug: Hyaluronic acid",
            "Biological: 100 million Bone marrow mesenchimal stem cells"
      ],
      "ArmGroupLabel": [
            "Hialuronic acid",
            "Hyaluronic acid and MSC 10",
            "Hyaluronic acid AND MSC 100"
      ],
      "ArmGroupType": [
            "Active Comparator",
            "Active Comparator",
            "Active Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT02123368"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Purpose: To determine the safety, feasibility and effectiveness (clinical and radiological) of intra-articular administration of autologous mesenchymal stem cells (MSCs) in patients with knee osteoarthritis.\n\nPatients and methods\n\nClinical trial phase I- II, randomized , multicenter , with three treatment arms and 10 patients for each group. The investigators compare the intraarticular injection of hialuronic acid against the administration of two different doses of mesenchymal stem cells with hialuronic acid according to the following scheme:\n\nGroup A: intra-articular injection of hyaluronic acid (Hyalone\u00ae). Single dose.\nGroup B: Low Dosage of MSCs . Intra-articular injection of 10 million autologous mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an intraarticular injection Hiaur\u00f3nico Acid ( Hyalone\u00ae).\nGroup C : High dose of MSCs. Intra-articular injection of 100 million autologous mesenchymal progenitor stem cells cultured ex - vivo ( cell suspension sterile small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an intraarticular injection Hiaur\u00f3nico Acid (Hyalone\u00ae).\n\nThe primary endpoint is safety and feasibility. The investigators registered the occurrence of complications and / or adverse effects during the study.\n\nIn addition the investigators assess the response to intra-articular infusion of CMM analyzing the following parameters:\n\nClinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.\nRadiographic (baseline, 6 and 12 months since treatment): Femorotibial space.\nRadiographic using MRI (baseline, 6 and 12 months since treatment): by assessing the number location of the lesions , cartilage thickness , signal intensity , subchondral bone alteration , volume and WORMS and dGEMRIC protocols."
      ],
      "BriefTitle": [
            "Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "February 2015"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Osteoarthritis"
      ],
      "ConditionAncestorId": [
            "D000001168",
            "D000007592",
            "D000009140",
            "D000012216"
      ],
      "ConditionAncestorTerm": [
            "Arthritis",
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC05",
            "All",
            "BC17"
      ],
      "ConditionBrowseBranchName": [
            "Musculoskeletal Diseases",
            "All Conditions",
            "Skin and Connective Tissue Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Osteoarthritis"
      ],
      "ConditionBrowseLeafId": [
            "M12078",
            "M21321",
            "M3628",
            "M9773",
            "M11249",
            "M14197",
            "M5475"
      ],
      "ConditionBrowseLeafName": [
            "Osteoarthritis",
            "Osteoarthritis, Knee",
            "Arthritis",
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases",
            "Collagen Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000010003"
      ],
      "ConditionMeshTerm": [
            "Osteoarthritis"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "Purpose: To determine the safety, feasibility and effectiveness (clinical and radiological) of intra-articular administration of autologous mesenchymal stem cells (MSCs) in patients with knee osteoarthritis.\n\nPatients and methods\n\nClinical trial phase I- II, randomized , multicenter , with three treatment arms and 10 patients for each group. The investigators compare the intraarticular injection of hialuronic acid against the administration of two different doses of mesenchymal stem cells with hialuronic acid according to the following scheme:\n\nGroup A: intra-articular injection of hyaluronic acid (Hyalone\u00ae). Single dose.\nGroup B: Low Dosage of MSCs . Intra-articular injection of 10 million autologous mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an intraarticular injection Hiaur\u00f3nico Acid ( Hyalone\u00ae).\nGroup C : High dose of MSCs. Intra-articular injection of 100 million autologous mesenchymal progenitor stem cells cultured ex - vivo ( cell suspension sterile small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an intraarticular injection Hiaur\u00f3nico Acid (Hyalone\u00ae).\n\nThe autologous mesenchymal stem cells are obtained from the iliac crest and cultured ex vivo under local anesthesia and sedation.\n\nThe primary endpoint is safety and feasibility. The investigators registered the occurrence of complications and / or adverse effects during the study.\n\nIn addition the investigators assess the response to intra-articular infusion of CMM analyzing the following parameters:\n\nClinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.\nRadiographic (baseline, 6 and 12 months since treatment): Femorotibial space.\nRadiographic using MRI (baseline, 6 and 12 months since treatment): by assessing the number location of the lesions , cartilage thickness , signal intensity , subchondral bone alteration , volume and WORMS and dGEMRIC protocols.\n\nAll patients met the following inclusion and exclusion criteria:\n\nInclusion Criteria:\n\nMales and females between 50 and 80 year old.\nDiagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American College of Rheumatology).\nJoint pain equal or greater than 2.5 points on the visual analogue scale (VAS).\nRadiological Classification: Kellgren-Lawrence scale greater or equal to 2.\nBody mass index between 20 and 35 kg/m2.\nAbility to follow during the study period.\n\nExclusion Criteria:\n\nBilateral Osteoarthritis of the Knee requiring treatment in both knees.\nPrevious diagnosis of polyarticular disease.\nSevere mechanical deformation.\nArthroscopy during the previous 6 months.\nIntraarticular infiltration of hyaluronic acid in the last 6 months.\nSystemic autoimmune rheumatic disease.\nPoorly controlled diabetes mellitus.\nBlood dyscrasias.\nImmunosuppressive or anticoagulant treatments.\nTreatment with corticosteroids in the 3 months prior to inclusion in the study.\nNSAID therapy within 15 days prior to inclusion in the study.\nPatients with a history of allergy to penicillin or streptomycin.\nAllergy to hyaluronic acid or poultry proteins."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nMales and females between 50 and 80 year old.\nDiagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American College of Rheumatology).\nJoint pain equal or greater than 2.5 points on the visual analogue scale (VAS).\nRadiological Classification: Kellgren-Lawrence scale greater or equal to 2.\nBody mass index between 20 and 35 kg/m2.\nAbility to follow during the study period.\n\nExclusion Criteria:\n\nBilateral Osteoarthritis of the Knee requiring treatment in both knees.\nPrevious diagnosis of polyarticular disease.\nSevere mechanical deformation.\nArthroscopy during the previous 6 months.\nIntraarticular infiltration of hyaluronic acid in the last 6 months.\nSystemic autoimmune rheumatic disease.\nPoorly controlled diabetes mellitus.\nBlood dyscrasias.\nImmunosuppressive or anticoagulant treatments.\nTreatment with corticosteroids in the 3 months prior to inclusion in the study.\nNSAID therapy within 15 days prior to inclusion in the study.\nPatients with a history of allergy to penicillin or streptomycin.\nAllergy to hyaluronic acid or poultry proteins."
      ],
      "EnrollmentCount": [
            "30"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000276",
            "D000007155",
            "D000045505",
            "D000055675",
            "D000020011"
      ],
      "InterventionAncestorTerm": [
            "Adjuvants, Immunologic",
            "Immunologic Factors",
            "Physiological Effects of Drugs",
            "Viscosupplements",
            "Protective Agents"
      ],
      "InterventionArmGroupLabel": [
            "Hialuronic acid",
            "Hyaluronic acid AND MSC 100",
            "Hyaluronic acid and MSC 10",
            "Hyaluronic acid and MSC 10",
            "Hyaluronic acid AND MSC 100"
      ],
      "InterventionBrowseBranchAbbrev": [
            "All"
      ],
      "InterventionBrowseBranchName": [
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [
            "Compression"
      ],
      "InterventionBrowseLeafId": [
            "M9030",
            "M2780",
            "M9353",
            "M27448",
            "M21022"
      ],
      "InterventionBrowseLeafName": [
            "Hyaluronic Acid",
            "Adjuvants, Immunologic",
            "Immunologic Factors",
            "Viscosupplements",
            "Protective Agents"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Single intraarticular injection of Hyaluronic acid (Hyal One)",
            "10 million of Bone marrow mesenchimal stem cells",
            "100 million of Bone marrow mesenchimal stem cells"
      ],
      "InterventionMeshId": [
            "D000006820"
      ],
      "InterventionMeshTerm": [
            "Hyaluronic Acid"
      ],
      "InterventionName": [
            "Hyaluronic acid",
            "10 million Bone marrow mesenchimal stem cells",
            "100 million Bone marrow mesenchimal stem cells"
      ],
      "InterventionOtherName": [
            "HyalOne"
      ],
      "InterventionType": [
            "Drug",
            "Biological",
            "Biological"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Osteoarthritis",
            "Mesenchimal stem cell",
            "Knee"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "October 24, 2017"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "October 23, 2017"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Clinica Universidad de Navarra, Universidad de Navarra"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Salamanca",
            "Pamplona"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Spain",
            "Spain"
      ],
      "LocationFacility": [
            "Traumatology department. Complejo Hospitalario de Salamanca",
            "Orthopaedic and traumatology department. Cl\u00ednica Universidad de Navarra"
      ],
      "LocationState": [
            "Castilla y Le\u00f3n",
            "Navarra"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "37007",
            "31008"
      ],
      "MaximumAge": [
            "80 Years"
      ],
      "MinimumAge": [
            "50 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Clinica Universidad de Navarra, Universidad de Navarra"
      ],
      "OrgStudyId": [
            "CMM/ART"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Clinica Universidad de Navarra",
            "Clinica Universidad de Navarra",
            "University of Salamanca"
      ],
      "OverallOfficialName": [
            "Jos\u00e9 Lamo-Espinosa, MD",
            "Felipe Prosper, MD PhD",
            "Juan Blanco, MD PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator",
            "Study Director",
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "November 2014"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Baseline Visual analogue scale (VAS)",
            "Prior to the intervention on day 1 value of knee injury and osteoarthritis outcome score (Koos).",
            "Prior to the intervention on day 1 Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).",
            "Prior to the intervention on day 1 SF-36 value",
            "Pretreatment euroquol 5D value",
            "Prior to the intervention on day 1 Lequesne index",
            "Prior to the intervention femoritibial distance on rosenberg x-ray view",
            "During the follow up",
            "Visual analogue scale (VAS) at on month",
            "Visual analogue scale (VAS) at 3 months",
            "Visual analogue scale (VAS) at 6 months",
            "Visual analogue scale (VAS) at 12 months",
            "Value of knee injury and osteoarthritis outcome score (Koos) at 1 month",
            "Value of knee injury and osteoarthritis outcome score (Koos) at 3 month",
            "Value of knee injury and osteoarthritis outcome score (Koos) at 6 month",
            "Value of knee injury and osteoarthritis outcome score (Koos) at 12 months",
            "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month",
            "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month",
            "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month",
            "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months",
            "SF-36 value",
            "SF 36 value at 3 months",
            "SF 36 value at 6 months",
            "SF 36 value at 12 months",
            "Euroquol 5D value at 1 month",
            "Euroquol 5D value at 3 months",
            "Euroquol 5D value at 6 months",
            "Euroquol 5D value at 12 months",
            "Lequesne index at 1 month",
            "Lequesne index at 3 months",
            "Lequesne index at 6 months",
            "Lequesne index at 12 months",
            "Femorotibial distance at 6 months",
            "Femorotibial distance at 12 months",
            "Prior to the intervention MRI WORMS protocol",
            "MRI WORMS protocol score at 6 months",
            "MRI WORMS protocol score at 12 months"
      ],
      "PrimaryOutcomeMeasure": [
            "Baseline Visual analogue scale (VAS)",
            "Baseline value of knee injury and osteoarthritis outcome score (Koos).",
            "Baseline Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).",
            "Baseline SF-36 value",
            "Baseline euroquol 5D value",
            "Baseline Lequesne index",
            "Baseline femorotibial distance",
            "Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events",
            "Visual analogue scale (VAS) at on month",
            "Visual analogue scale (VAS) at 3 months",
            "Visual analogue scale (VAS) at 6 months",
            "Visual analogue scale (VAS) at 12 months",
            "Value of knee injury and osteoarthritis outcome score (Koos) at 1 month",
            "Value of knee injury and osteoarthritis outcome score (Koos) at 3 month",
            "Value of knee injury and osteoarthritis outcome score (Koos) at 6 month",
            "Value of knee injury and osteoarthritis outcome score (Koos) at 12 months",
            "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month",
            "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 3 month",
            "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month",
            "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months",
            "SF-36 value at 1 month",
            "SF 36 value at 3 months",
            "SF 36 value at 6 months",
            "SF 36 value at 12 months",
            "Euroquol 5D value at 1 month",
            "Euroquol 5D value at 3 months",
            "Euroquol 5D value at 6 months",
            "Euroquol 5D value at 12 months",
            "Lequesne index at 1 month",
            "Lequesne index at 3 months",
            "Lequesne index at 6 months",
            "Lequesne index at 12 months",
            "Femorotibial distance at 6 months",
            "Femorotibial distance at 12 months",
            "Baseline MRI WORMS protocol",
            "MRI WORMS protocol score at 6 months",
            "MRI WORMS protocol score at 12 months"
      ],
      "PrimaryOutcomeTimeFrame": [
            "prior to the initial dose on day 1",
            "Prior to the intervention on day 1",
            "Prior to the intervention on day 1",
            "Prior to the intervention on day 1",
            "Prior to the intervention on day 1",
            "Prior to the intervention on day 1",
            "Prior to the intervention",
            "Follow up",
            "1 month",
            "3 months",
            "6 months",
            "12 months",
            "1 month",
            "3 Months",
            "6 months",
            "12 months",
            "1 month",
            "3 months",
            "6 months",
            "12 months",
            "1 month",
            "3 months",
            "6 months",
            "12 months",
            "1 MOnth",
            "3 months",
            "6 months",
            "12 months",
            "1 month",
            "3 months",
            "6 months",
            "12 months",
            "6 months",
            "12 months",
            "Prior to the intervention",
            "6 months",
            "12 months"
      ],
      "ReferenceCitation": [
            "Lamo-Espinosa JM, Pr\u00f3sper F, Blanco JF, S\u00e1nchez-Guijo F, Alberca M, Garc\u00eda V, Gonz\u00e1lez-Vallinas M, Garc\u00eda-Sancho J. Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis. J Transl Med. 2021 Dec 11;19(1):506. doi: 10.1186/s12967-021-03160-2.",
            "Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Molt\u00f3 F, N\u00fa\u00f1ez-C\u00f3rdoba JM, L\u00f3pez-El\u00edo S, Andreu E, S\u00e1nchez-Guijo F, Aquerreta JD, Bond\u00eda JM, Valent\u00ed-Azc\u00e1rate A, Del Consuelo Del Ca\u00f1izo M, Villar\u00f3n EM, Valent\u00ed-Nin JR, Pr\u00f3sper F. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II). J Transl Med. 2018 Jul 31;16(1):213. doi: 10.1186/s12967-018-1591-7.",
            "Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Molt\u00f3 F, Nu\u00f1ez-C\u00f3rdoba JM, S\u00e1nchez-Echenique C, Bond\u00eda JM, Aquerreta JD, Andreu EJ, Ornilla E, Villar\u00f3n EM, Valent\u00ed-Azc\u00e1rate A, S\u00e1nchez-Guijo F, Del Ca\u00f1izo MC, Valent\u00ed-Nin JR, Pr\u00f3sper F. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II). J Transl Med. 2016 Aug 26;14(1):246. doi: 10.1186/s12967-016-0998-2."
      ],
      "ReferencePMID": [
            "34895259",
            "30064455",
            "27565858"
      ],
      "ReferenceType": [
            "derived",
            "derived",
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "2009-017624-72"
      ],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [
            "EudraCT Number"
      ],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [],
      "SecondaryOutcomeTimeFrame": [],
      "SeeAlsoLinkLabel": [
            "University clinic of navarre trial information"
      ],
      "SeeAlsoLinkURL": [
            "http://www.cun.es/actualidad/noticias/celulas-madre-osea-artrosis-rodilla"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "May 2012"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "October 2017"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "April 25, 2014"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "November 12, 2013"
      ],
      "StudyFirstSubmitQCDate": [
            "April 23, 2014"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}